
Tiffany Wang, MD, MBA, MS
Clinical Development
Haofei Tiffany Wang, MD, MS, MBA is executive Director of Clinical Development at Aktis Oncology, bringing over 20 years of oncology experience from both large pharmaceutical companies and biotech firms, with expertise as both a medical lead and statistical expert.
Before joining Aktis, Tiffany was Vice President of Clinical Development at Tango Therapeutics, where she led two first-in-human precision oncology programs. Previously, she served as Senior Medical Director at Omega Therapeutics, directing the company’s initial clinical-stage epigenomic mRNA programs for hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC). Earlier in her career, Tiffany spent six years at Ipsen, where she was the medical lead for pivotal Phase III trial in small cell lung cancer (SCLC) and the statistical lead for pivotal Phase III pancreatic cancer trial, which led to successful sNDA registration. Tiffany began her industry career with a decade-long tenure at Eli Lilly as a biostatistician in early-phase oncology.
Dr. Wang earned her MD from Capital Medical University in Beijing, China, and holds MS degrees in Statistics and Biochemistry from the University of Georgia. She also holds an MBA from Indiana University’s Kelley School of Business.
At Aktis, Tiffany hopes to leverage her extensive clinical development and statistical expertise to drive advancements in targeted radiopharmaceuticals